Literature DB >> 21422013

Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: a prospective cohort study.

Gustavo Lamego de Barros Costa1, Diana Carvalho Ferreira, Reginaldo Aparecido Valacio, Maria da Consolação Vieira Moreira.   

Abstract

BACKGROUND: despite the overwhelming evidence of its effectiveness, oral anticoagulation continues to be underused in the elderly, presumably due to physicians' misconceptions when estimating bleeding risk and ability to comply with treatment.
OBJECTIVE: to investigate the quality of anticoagulation control among deprived elderly and younger patients.
DESIGN: prospective observational study.
SETTING: a public anticoagulation clinic in a developing country.
SUBJECTS: all adult patients on intended long-term (>90 days) oral anticoagulation. We studied 171 patients (79 elderly and 92 non-elderly) with a mean follow-up of 273 ± 84.9 days.
METHODS: the main outcome measure was the quality of anticoagulation management as measured by the time in therapeutic (TTR) international normalised ratio (INR) range. Elderly patients (≥60 years) were compared with younger patients with respect to the educational level and co-morbidities.
RESULTS: the mean number of years of formal education was 4.37 ± 3.2 years. The mean TTR was 62.50 ± 17.9% in non-elderly and 62.10 ± 16.6% in elderly (P = 0.862) subjects, despite the higher prevalence of co-morbidities in the latter group: heart failure (46.3 versus 28.6%, P = 0.042), diabetes mellitus (22.8 versus 8.7%, P = 0.011), renal failure (estimated glomerular filtration rate <50 ml/min: 38.0 versus 7.1%, P < 0.001) and polypharmacy (84.8 versus 58.7%, P < 0.001). Fifty elderly and 84 non-elderly subjects require little or no assistance in taking medications. Among them, the elderly had lower educational levels (3.42 ± 2.5 versus 5.55 ± 3.4 years of formal education, P < 0.001) and higher rates of cognitive impairment (34.0 versus 13.1%, P = 0.004), but a similar mean TTR (62.46 ± 16.1 versus 63.02 ± 17.8%, P = 0.856). The oldest (≥75 years) patients did as well as those aged ≤50 years (mean TTR: 62.54 ± 16.0 versus 62.23 ± 16.4%, respectively, P = 0.98).
CONCLUSIONS: good-quality management of oral anticoagulation is achievable in deprived populations attending an anticoagulation clinic. Elderly patients may experience similar quality of anticoagulation despite having higher levels of co-morbidities and polypharmacy. These results add evidence to the safety of such therapeutic interventions in the elderly.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422013     DOI: 10.1093/ageing/afr020

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  4 in total

1.  Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.

Authors:  Renato D Lopes; Richard C Becker; L Kristin Newby; Eric D Peterson; Elaine M Hylek; Robert Giugliano; Christopher B Granger; Kenneth W Mahaffey; Antonio C Carvalho; Otavio Berwanger; Roberto R Giraldez; Gilson Soares Feitosa-Filho; Marcia M Barbosa; Maria da Consolacao V Moreira; Renato A K Kalil; Marildes Freitas; Joao Carlos de Campos Guerra; Marcio Vinicius Lins Barros; Thiago da Rocha Rodrigues; Antonio C Lopes; David A Garcia
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

2.  Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study.

Authors:  Eveline Hofmann; Nicolas Faller; Andreas Limacher; Marie Méan; Tobias Tritschler; Nicolas Rodondi; Drahomir Aujesky
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

3.  Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics.

Authors:  Salih Kılıç; Hatice Soner Kemal; Elif İlkay Yüce; Evrim Şimşek; Burcu Yağmur; Nuray Memişoğlu Akgül; Cahide Soydaş Çınar; Mehdi Zoghi; Cemil Gürgün
Journal:  Anatol J Cardiol       Date:  2017-11       Impact factor: 1.596

4.  Efficacy and safety of dabigatran versus warfarin from the RE-LY trial.

Authors:  Alvaro Avezum; Gustavo Bernardes de Figueiredo Oliveira; Rafael Diaz; Jesus Antonio Gonzalez Hermosillo; Jonas Oldgren; Ernesto Ferreiros Ripoll; Herbert Noack; Leopoldo Soares Piegas; Stuart J Connolly
Journal:  Open Heart       Date:  2018-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.